Based in Dijon, France, the Center will boast a unique offering for drug discovery in Europe, combining Inventiva’s screening platforms and libraries with SensiQ’s instrumentation

SensiQ, a leader in surface plasmon resonance (SPR) technologies and Inventiva, a French drug discovery company focused on therapeutic approaches involving transcription factors and epigenetic targets, today announce the launch of a European Center of Excellence in SPR technologies, using SensiQ^® Pioneer Fragment Edition (Pioneer FE) instrumentation.

The SPR Center of Excellence is based in Dijon, France. Inventiva’s existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva’s current service offering. The new Center also allows SensiQ to offer prospective customers on-site demonstrations at Inventiva’s offices. Inventiva’s entire team will benefit from the extensive SPR experience from the SensiQ dedicated support staff.

“The Center of Excellence will provide additional technological capabilities to our partners. It also enhances our extensive HTS and HCS screening platforms, which, combined with our proprietary library, provide one of the most compelling offerings available on the market”, said Frederic Cren, co-founder and CEO of Inventiva. “We look forward to using the SensiQ Pioneer equipment. It provides us with a powerful tool to measure binding interactions and accelerate drug discovery for our partners”, said Pierre Broqua, co-founder and CSO of Inventiva.

“The newly released Pioneer FE represents a new paradigm in capability and performance. We are thrilled that Inventiva has chosen to make it the centerpiece of the SPR Center of Excellence in Dijon”, said Colin Cumming, CEO of SensiQ.

About SensiQ Technologies

SensiQ Technologies is a provider of bioinstrumentation to accelerate drug discovery and development. These systems provide real-time, label-free analysis of biomolecular interactions. SensiQ Technologies products enable robust, rapid, and precise affinity characterization of drug candidates. In particular, the flagship Pioneer FE incorporating the breakthrough OneStep^® innovation represents the industry leading instrumentation focused on Fragment Based Drug Discovery. 

About Inventiva

Inventiva is a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets (particularly the HKMT family) to discover innovative treatments for cancer, fibrosis, immuno-inflammatory diseases and Parkinson’s disease. The company’s business strategy is to engage in proprietary research programs and secure drug discovery partnerships with pharmaceutical groups. It also offers a full range of research services. These draw on its extensive technology platform, a proprietary library of 240,000 compounds and a fibrosis platform. Inventiva also has expertise in nuclear receptors, transcription factors and epigenetic modulation. Over 100 employees are based at its research center in Daix, near Dijon (France).

more about sensiQ

more about inventiva